Novartis Injects Itself Into Planned Rollout of EpiPen Rival

Adamis Pharmaceuticals agreed to sell the U.S. commercial rights for Symjepi, an epinephrine injector for the emergency treatment of allergic reactions, to Sandoz, a Novartis subsidiary.

from WSJ.com: US Business https://ift.tt/2KqVMSf
via IFTTT